The Valley Desk

NCT02252263 · Interventional trial

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Overall registry status Completed

Phase 1

Conditions Multiple Myeloma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov